Pharmamarketeer

European Commission approves treatment of unresectable uveal melanoma

Melanoma

Immunocore Holdings has announced that the European Commission has approved KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatcv uveal melanoma (mUM).

Kimmtrack is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function.

read more

Medhc-fases-banner
Advertentie(s)